FDA Approves New Oral Medication for Rare Genetic Bone Condition

The U.S. FDA has approved Atebrioz (zilurgisertib) tablets for patients aged 12 and older with Fibrodysplasia Ossificans Progressiva (FOP). This once-daily oral ALK2 inhibitor aims to reduce abnormal bone formation in soft tissues, a hallmark of the ultra-rare genetic disease affecting around 300 Americans. This approval provides a new therapeutic option for a condition with limited treatments.